{"id":249788,"date":"2023-09-21T00:00:00","date_gmt":"2023-09-21T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcv0007-biopharma-chronic-heart-failure-epidemiology-mature\/"},"modified":"2026-03-31T10:32:10","modified_gmt":"2026-03-31T10:32:10","slug":"epidcv0007-biopharma-chronic-heart-failure-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcv0007-biopharma-chronic-heart-failure-epidemiology-mature-markets\/","title":{"rendered":"Chronic Heart Failure &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of chronic heart failure (<abbr title=\"chronic heart failure\">CHF<\/abbr>) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the prevalence of <span class=\"ice-ins ice-cts-1\" data-changedata=\"\" data-cid=\"2\" data-last-change-time=\"1703089211708\" data-time=\"1703089210855\" data-userid=\"3375\" data-username=\"Sarah\"><abbr title=\"chronic heart failure\">CHF<\/abbr> <\/span>for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets covered in this report.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"chronic heart failure\">CHF<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people diagnosed with <abbr title=\"chronic heart failure\">CHF<\/abbr>, how many in each of the major mature pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"chronic heart failure\">CHF<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides 20 years of forecast data for the following <abbr title=\"chronic heart failure\">CHF<\/abbr> subpopulations:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed prevalent cases of <abbr title=\"chronic heart failure\">CHF<\/abbr> by comorbid atrial fibrillation (<abbr title=\"atrial fibrillation\">AF<\/abbr>)<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"chronic heart failure\">CHF<\/abbr> by comorbid chronic obstructive pulmonary disease (<abbr title=\"chronic obstructive pulmonary disease\">COPD<\/abbr>)<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"chronic heart failure\">CHF<\/abbr> by comorbid diabetes<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"chronic heart failure\">CHF<\/abbr> by comorbid hypertension<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"chronic heart failure\">CHF<\/abbr> by comorbid coronary heart disease (<abbr title=\"coronary heart disease\">CHD<\/abbr>)<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"chronic heart failure\">CHF<\/abbr> by comorbid dyslipidemia<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"chronic heart failure\">CHF<\/abbr> by history of myocardial infarction (<abbr title=\"myocardial infarction\">MI<\/abbr>)<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"chronic heart failure\">CHF<\/abbr> by history of stroke<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"chronic heart failure\">CHF<\/abbr> by comorbid obesity<\/li>\n<li>Diagnosed prevalent <abbr title=\"chronic heart failure\">CHF<\/abbr> cases by New York Heart Association (<abbr title=\"New York Heart Association\">NYHA<\/abbr>) functional classification status<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"chronic heart failure\">CHF<\/abbr> characterized by reduced ejection fraction (<abbr title=\"ejection fraction\">EF<\/abbr>)<\/li>\n<li>Diagnosed prevalent cases of <abbr data-abbreviation-entity=\"4761\" title=\"chronic heart failure\">CHF<\/abbr> characterized by preserved or mid-range <abbr title=\"ejection fraction\">EF<\/abbr><\/li>\n<li>\u2026 and more (details available on request)<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-249788","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-cardiovascular","biopharma-therapy-areas-chronic-heart-failure","biopharma-therapy-areas-heart-failure","biopharma-product-epidemiology","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249788","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249788\/revisions"}],"predecessor-version":[{"id":403667,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249788\/revisions\/403667"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249788"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}